Organic compounds -- part of the class 532-570 series – Organic compounds – Nitrogen attached directly or indirectly to the purine ring...
Reexamination Certificate
2007-01-09
2007-01-09
McKenzie, Thomas C. (Department: 1624)
Organic compounds -- part of the class 532-570 series
Organic compounds
Nitrogen attached directly or indirectly to the purine ring...
Reexamination Certificate
active
10654546
ABSTRACT:
In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
REFERENCES:
patent: 5571813 (1996-11-01), Rühter et al.
patent: 5602136 (1997-02-01), Rühter et al.
patent: 5602137 (1997-02-01), Ruhter et al.
patent: 5688949 (1997-11-01), Inoue et al.
patent: 5707997 (1998-01-01), Shoji et al.
patent: 5919815 (1999-07-01), Bradley et al.
patent: 6040321 (2000-03-01), Kim et al.
patent: 6107305 (2000-08-01), Misra et al.
patent: 6191131 (2001-02-01), He et al.
patent: 6262096 (2001-07-01), Kim et al.
patent: 6413974 (2002-07-01), Dumont et al.
patent: 102 23 917 (2003-12-01), None
patent: 0 628 559 (1994-12-01), None
patent: 0 628 559 (2002-04-01), None
patent: 1 334 973 (2003-08-01), None
patent: 1412017 (1975-10-01), None
patent: 61-57587 (1986-03-01), None
patent: WO 95/35298 (1995-12-01), None
patent: WO 02/40485 (2002-05-01), None
patent: WO 02/50079 (2002-06-01), None
patent: WO 02/50079 (2002-06-01), None
patent: WO 03/091256 (2003-11-01), None
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
Peter M Fischer, Athos Gianella-Borradori, Expert Opinion on Investigational Drugs, Apr. 2005, vol. 14, No. 4, pp. 457-477.
Peter M Fischer, Athos Gianella-Borradori, Expert Opinion on Investigational Drugs, Jun. 2003, vol. 12, No. 6, pp. 955-970.
Vesely et al., “Inhibition of Cyclin-Dependent Kinases by Purine Analogues”,Eur. J. Biochem(1994), 224: 771-786.
Kim et al., “Discovery of Aminothiazole Inhibitors of Cyclin-Dependent Kinase 2: Synthesis, X-ray Crystallographic Analysis, and Biological Activities”,Journal of Medical Chemistry, p. EST:22.3, A-W.
Mettey et al., “Aloisines, a New Family of CDK/GSK-3 Inhibitors. SAR Study, Crystal Structure in Complex with CDK2, Enzyme Selectivity, and Cellular Effects”,J. Med. Chem. (2003), 46(2): 222-236.
Novinson et al., “Synthesis and Antifungal Properties of Certain 7-Alkylaminopyrazolo[1.5-α]pyrimidines”,J. Med. Chem. (1977), 20(2): 296-299.
Senderowicz et al., “Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhitibor, in Patients with Refractory Neoplasms”,Journal of Clinical Oncology(Sep. 1998), 16(9): 2986-2999.
Meijer et al., “Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases CDC2, CDK2 and CDK5”,Eur. J. Biochem. (1997), 243:527-536.
Bible et al., “Cytotoxic Synergy Between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: The Importance of Sequence of Administration”,Cancer Research(Aug. 15, 1997), 57: 3375-3380.
Shiota et al., “Synthesis and Structure-Activity Relationship of a New Series of Potent Angiotensin II Receptor Antagonists: Pyrazolo[1.5-α]pyrimidine Derivatives”,Chem. Pharm. Bull. (1999), 47(7): 928-938.
Yasuo Makisumi, “Studies on the Azaindolizine Compounds. XI. Synthesis of 6,7-Disubstituted Pyrazolo[1.5-α]pyrimidines.”,Chem. Pharm. Bull(1962), 10: 620-626.
Translation of WO 03/91256,A Rising Sun Communications Ltd. Translation Product, (1-62).
Alvarez Carmen S.
Chan Tin-Yau
Dillard Lawrence W.
Doll Ronald J.
Dwyer Michael P.
Kalyanaraman Palaiyur S.
McKenzie Thomas C.
Pharmacopeia Drug Discovery Inc.
Schering Corporation
LandOfFree
Pyrazolopyrimidines as cyclin dependent kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazolopyrimidines as cyclin dependent kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazolopyrimidines as cyclin dependent kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3820611